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So far 18 MLH3 germline mutations/variants have been identiﬁed in familial colorectal cancer cases. Sixteen of these var-
iants are amino acid substitutions of which the pathogenic nature is still unclear. These substitutions are known as unclassi-
ﬁed variants or UVs. To clarify a possible role for eight of these MLH3 UVs identiﬁed in suspected Lynch syndrome
patients, we performed several biochemical tests. We determined the protein expression and stability, protein localization
and interaction of the mutant MLH3 proteins with wildtype MLH1. All eight MLH3 UVs gave protein expression levels
comparable with wildtype MLH3. Furthermore, the UV-containing proteins, in contrast to previous studies, were all
localized normally in the nucleus and they interacted normally with wildtype MLH1. Our different biochemical assays
yielded no evidence that the eight MLH3 UVs tested are the cause of hereditary colorectal cancer, including Lynch
syndrome. VC 2009 Wiley-Liss, Inc.
INTRODUCTION
Mismatch repair (MMR) proteins form a highly
conserved group of proteins that play a crucial
role in correcting DNA mismatches that have
escaped the proofreading activity of DNA poly-
merases. In the human MMR system the mis-
match recognition component is fulﬁlled by a
heterodimeric protein complex composed of two
MutS homologous (MSH) proteins. The major
MSH-heterodimer consists of MSH2 and MSH6
(MUTSa). This heterodimer is able to recognize
and bind to base-base mismatches as well as to
small insertion/deletion loops. A minor and par-
tially redundant mismatch recognizing/binding
heterodimer called MUTSb consists of the
MSH2 and MSH3 proteins. This protein complex
recognizes and binds mainly to larger insertion/
deletion loops (Chung and Rustgi, 2003). During
the mismatch repair process, when MUTSa/
MUTSb recognize DNA mismatches that arise
during DNA replication, the protein complex
binds to the mismatch, thereby inducing a con-
formational change of the heterodimer and allow-
ing ATP to bind and activate the protein
complex. After activation of the MUTS complex,
a heterodimer of two MutL homologous (MLH)
proteins will bind to the DNA/protein complex.
Two heterodimers composed of either MLH1 or
PMS2 (MUTLa) or MLH1 and MLH3
(MUTLc) are proven interactors with the MSH2-
containing DNA-protein complex. These MLH
complexes are thought to coordinate the down-
stream repair events, involving different proteins
such as exonucleases (e.g., EXO1) and DNA poly-
merases (Tishkoff et al., 1997; Tran et al., 2001;
Liberti and Rasmussen, 2004). The heterodimer
MLH1-PMS2 (MUTLa) interacts with both
MUTSa and MUTSb, whereas the heterodimer
MLH1-MLH3 (MUTLc) is believed to partici-
pate in insertion/deletion loop (IDL) repair
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and to primarily function in conjunction with
MSH2-MSH3 (Flores-Rozas and Kolodner, 1998;
Harfe et al., 2000).
Chen et al. (2005), showed in mice that Mlh3
deﬁciency causes microsatellite instability,
impaired DNA damage response, and increased
gastrointestinal tumor susceptibility. Results
obtained in recent in vivo studies show that Mlh3
deﬁciency increases the mutation frequency of
insertion-deletion loops. Furthermore, a primary
role for the Mlh1-Mlh3 heterodimer in suppres-
sion of gastrointestinal tumor initiation in mice
has been suggested (Chen et al., 2008). In addi-
tion, cultured mammalian cells, stably expressing
a dominant negative truncated human MLH3,
showed microsatellite instability (MSI) (Lipkin
et al., 2000). In contrast, the effect of loss-of-
function mutations in yeast indicates a minor role
for the MLH3 yeast protein (Mlh3p) in MMR
(Flores-Rozas and Kolodner, 1998; Harfe et al.,
2000). For an excellent review on the MMR pro-
cess in humans see (Jiricny, 2006).
Loss of MMR proteins results in the accumula-
tion of unrepaired mutations. It is therefore not
unexpected that mutations in these MMR genes
are associated with tumor development. Germline
mutations in four MMR genes, namely MLH1,
MSH2, PMS2, and MSH6, have been identiﬁed in
the majority of families with hereditary nonpoly-
posis colorectal cancer or Lynch syndrome (Pelto-
maki and Vasen, 2004). Many of the mutations
identiﬁed result in premature termination of
translation and thus in loss-of-function of the
encoded mutated protein. This loss of MMR
function results in unrepaired mutations in non-
coding but also in coding sequences. It is mainly
these coding sequence mutations that contribute
to tumor development (Perucho, 1999).
Recently, we identiﬁed nine MLH3 missense
mutations and an MLH3 frameshift mutation in
patients suspected of having Lynch syndrome
(Wu et al., 2001). The missense mutations will
be called UVs throughout this article because it
is not yet known whether these DNA variants
contribute to disease development. Identifying
these DNA variants, in combination with the
identiﬁcation of somatic MLH3 mutations in
three tumors of patients with these DNA variants
(Wu et al., 2001), led us to hypothesize that,
besides the four known MMR genes, MLH3
might also play a role in Lynch syndrome devel-
opment. This thought is further strengthened by
other articles describing the association of germl-
line MLH3 mutations with esophageal, colorectal
and endometrial cancer susceptibility (Liu et al.,
2006; Taylor et al., 2006; Kim et al., 2007). How-
ever, as all but two of the variations identiﬁed so
far were UVs, the role of MLH3 in the develop-
ment of Lynch syndrome is still under debate.
We biochemically tested eight identiﬁed MLH3
UVs to see whether there is a possible role for
MLH3 in Lynch syndrome.
MATERIALS AND METHODS
Cell Lines
HEK293T cells, human embryonic kidney cells
that lack MLH1 and MLH3 expression due to hy-
permethylation of the promoter regions of both
genes (Cannavo et al., 2005), were grown in
DMEM, supplemented with 10% fetal bovine se-
rum, 1% penicillin-streptomycin and L-Glutamine
(all from Invitrogen, Breda, the Netherlands).
HeLa cells (ATCC CCL-2; a cervical carcinoma
cell line) were grown in DMEM containing 10%
FBS and 1% penicillin-streptomycin (all from
Gibco, Taastrup, Denmark).
In Silico Analysis of the Unclassiﬁed
Variants in MLH3
A description of the different MLH3 UVs that
were tested and the clinical characteristics of the
mutation carriers are given in Table 1 and in Fig-
ure 1. Alignments with MLH3 homologous pro-
teins from six other vertebrates were obtained by
blasting the complete MLH3 protein to assess
whether the variant amino acids had been evolu-
tionarily conserved. The program used was M-
Coffee (http://www.tcoffee.org) (Moretti et al.,
2007). The following sequences were used in the
Blast search: Homo sapiens, Rattus norvegicus, Mus
musculus, Canis familiaris, Bos taurus, Gallus gallus,
Xenopus tropicalis, Pan troglodytes, and Saccharomy-
ces cerevisiae.
All eight MLH3 UVs were further analyzed in
silico for putative functional effects by determin-
ing the Grantham’s chemical distance that con-
siders composition, polarity and volume
(Grantham, 1974) and by using the Align GVGD
algorithm (Grantham variation and Grantham
deviation), a web-based program that combines
the biophysical characteristics of amino acid and
protein multiple sequence alignments to predict
where missense substitutions in genes of interest
fall in a spectrum from enriched deleterious to
enriched neutral (http://agvgd.iarc.fr/agvgd_
input.php; Tavtigian et al., 2005; Mathe et al.,
2006). We also evaluated the biochemical effects
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of the amino acid substitutions by the ‘‘Russel
method’’ at EMBL (http://www.russell.embl-
heidelberg.de/aas/; Betts and Russell, 2003).
Additionally, we used the polymorphism pheno-
typing (PolyPhen) algorithm (http://genetics.bwh.
harvard.edu/pph). PolyPhen is a web-based algo-
rithm that predicts how an amino acid substitu-
tion could possibly affect the structure and
function of a human protein using straightforward
physical and comparative considerations. Calcula-
tions are based on amino acid homology and
structure databases and three-dimensional struc-
ture databases. In silico analysis using the Poly-
Phen algorithm was done on the entire MLH3
protein sequence. Amino acid substitutions are
reported as benign, possibly damaging or probably
damaging. The variants were also assessed by
using the ‘‘Sort Intolerant From Tolerant’’ (SIFT)
algorithm by submitting aligned sequences at the
SIFT server. SIFT uses sequence homology and
the physical properties of amino acids to predict
the effect of amino acid substitutions.
Three web-based algorithms were used to





splice.html). As input we gave a fragment contain-
ing the exon sequence plus 200 nucleotides
upstream and 200 bp downstream of the exon.
This was done for exons 1, 11, and 12 since the
eight UVs tested lie within these exons.
We also ran ESEﬁnder (http://rulai.cshl.
edu/cgi-bin/tools/ESE3/eseﬁnder.cgi?process¼home),
a program that searches for sequences that act as
binding sites for four members of the serine/argi-
nine rich family of splicing enhancer proteins.
Input sequences are screened for consensus bind-
ing sequences for the SR proteins CF2/ASF,
SC35, SRp40, and SRp55. Regions with scores
above a certain threshold value are predicted to
act as SR protein binding sites, and thus function
as ESEs (exonic splice enhancers). The wildtype
(or UV-containing) MLH3 cDNA sequence (AB
039667) was used as input. The program was run
in an exon-by-exon manner.
MLH3 Vectors and MLH3 Mutants
To clone the MLH3 cDNA (wildtype) in pAS2
(a yeast two-hybrid vector containing a GAL4
DNA binding domain) and pACT2 (a yeast two-
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domain), MLH3 was ﬁrst cloned into pBluescript.
MLH3 was PCR-ampliﬁed using primers contain-
ing the 50 end and the 30 end of the coding
sequence coupled to a BamHI (forward) and an
Eco47III (reverse) restriction site. An extra AG
was inserted between the BamHI site and the
ﬁrst codon of MLH3 (to get MLH3 in the correct
reading frame after subsequent subcloning into
pACT2 and pAS2). After cloning this PCR-ampli-
ﬁed MLH3 in pBluescript, the insert was
sequenced and subcloned in pACT2 and pAS2
using the BamHI and Eco47III restriction sites.
Mutations [i.e., the eight UVs mentioned in Ta-
ble 1, one known polymorphic missense variant
(p.Ser845Gly) and the identiﬁed frameshift muta-
tion (see Table 1)] were introduced in these plas-
mids using the Stratagene QuickChange XL
Mutagenesis Kit (La Jolla, CA). This was done
according to the manufacturer’s instructions. After
mutagenesis the MLH3 inserts were sequenced to
conﬁrm the mutation status of the plasmids.
Wildtype MLH3 (from pBluescript-MLH3) was
cloned directly, in-frame with YFP, into
pEYFPC1 (Clontech Laboratories, Woerden, the
Netherlands) and the constructed YFP-MLH3
vector was used for subcellular localization stud-
ies. Mutations [(i.e., the eight UVs mentioned in
Table 1, one known polymorphic missense vari-
ant (p.Ser845Gly) and the truncating mutation we
identiﬁed (see Table 1)] were introduced in WT-
YFP-MLH3 using the Stratagene QuickChange
XL Mutagenesis Kit (La Jolla, CA). This was
done according to the manufacturer’s instructions.
After mutagenesis all inserts were veriﬁed by
sequencing.
Protein Expression of MLH3
in the HEK293T Cell Line
HEK293-T cells were seeded in a 6-well plate
24 hr before transfection to ensure 60% conﬂu-
ence on the day of transfection. Four micrograms
of YFP-MLH3 vector (WT or mutant) was trans-
fected using 10 ll Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA). WT-CFP-MLH1 and WT-
YFP-MLH3 were used as positive controls.
Transfected HEK293T cells were lysed 48 hr af-
ter transfection using a nondenaturing lysis buffer
(20 mM Tris-HCl, pH 8, 135 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, 1% Triton X-100, 10%
glycerol, protease inhibitors). Protein concentra-
tion determinations were performed according to
Bradford (1976) and 75 lg of the cell lysate was
loaded and size separated on a 6% SDS-PAGE
gel. After separation by SDS-PAGE, proteins
were transferred to a nitrocellulose membrane
(Bio-Rad, Veenendaal, the Netherlands). MLH3
was detected with speciﬁc antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA) or with
anti-GFP (GeneTex, San Antonio, TX) and
anti-mouse IgG HRP-conjugated secondary anti-
body (Pierce Biotechnology, Rockford). Beta-
tubulin (a housekeeping protein) was used as an
internal loading control and detected with an
anti-beta-tubulin antibody (Sigma-Aldrich, St.
Louis, MO) and anti-mouse IgG HRP-conju-
gated secondary antibody (Pierce Biotechnology,
Rockford). Signal visualization was performed
with the Supersignal West Dura Extended Du-
ration Substrate kit (Pierce Biotechnology,
Rockford).
Figure 1. Schematic representation of the MLH3 exon map (upper
panel) and the MLH3 protein and location of the tested MLH3 UVs,
the known polymorphism (in italics), and the truncating mutation in
the protein. The green parts in the exon map represent the noncod-
ing regions of exon 1 and exon 13. The light blue parts of the protein
represent the MLH1 interaction domains obtained from Kondo et al.
(2001). [Color ﬁgure can be viewed in the online issue, which is avail-
able at www.interscience.wiley.com.]
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Subcellular Localization of MLH3
On the day prior to transfection, 100,000 cells
were seeded in small glass Petri dishes (20 mm
in diameter). On the day of transfection, the
media were refreshed. For transfection 1 lg of
plasmid DNA (also 1 lg in total for the double
transfection experiments) and 3 ll Fugene6 per
Petri dish was used. Fugene6 (3 ll) was mixed
with 50 ll optimem and incubated for 5 min at
room temperature. DNA was added and mixed,
and this mixture was incubated for 20 min after
which it was added to the cells. The cells were
then incubated for 24 hr. After incubation, the
transiently expressed, ﬂuorescently labeled pro-
teins were visualized by confocal laser scanning
microscopy (Zeiss LSM510, Carl Zeiss MicroI-
maging GmbH, Jena, Germany).
Yeast Two Hybrid Analysis
To investigate the ability of UV-containing
MLH3 proteins to form MLH1-MLH3 hetero-
dimers, yeast two-hybrid assays were performed
essentially as described by Rasmussen et al.,
(2000). pAS2-MLH1 and pACT2-MLH3 were
cotransformed into the Saccharomyces cerevisiae
strain Y190. Transformants were selected on syn-
thetic dextrose minimal medium (SD) lacking
tryptophan, leucine and histine (SD/-Trp/-Leu/
-His). At least ﬁve colonies were streaked onto an
SD/-Trp/-Leu/-His plate that was supplemented
with 25 mM 3-amino-1,2,4-triazole(3-AT). Colo-
nies were further tested on SD/-Trp/-Leu/-His/3-
AT þ40 lg/ml 5-bromo-4-chloro-3-indolyl-b-D-ga-
lactosidase (X-gal) plates. Blue colonies that can
grow on these selection plates express GAL4-
tagged proteins that are able to interact. Several
attempts to introduce pACT2-MLH3 p.E1451K
into Y190 failed. The reason for this is unknown.
The two-hybrid vectors containing MLH3 or
MLH1, in combination with the empty vectors,
were used as negative controls.
RESULTS
In Silico Analysis of the Unclassiﬁed
Variants in MLH3
The alignment depicted in Figure 2 shows that
one of the eight UVs changed a reasonably well-
conserved amino acid (p.Gly981Ser), whereas the
other seven of the eight UVs changed highly con-
served amino acids. The results of the other in
silico analyses of the MLH3 UVs are presented
in Table 2. The Grantham scores and the
‘‘Russel’s prediction’’ show that all amino acid
substitutions are not likely to interfere with the
function of MLH3. Seven of the eight UVs were
predicted to be benign based on PolyPhen. Only
UV, p.Asn499Ser, was predicted to be possibly
damaging based on the PolyPhen algorithm.
Although SIFT predicts effects on protein func-
tion for p.Gln24Glu and p.Ala1394Thr, these pre-
dictions have a low conﬁdence.
An in silico study for the possible splicing
effects of the UVs, as determined by Netgene2,
Splicesiteﬁnder, Splice Site Predict and ESE-
ﬁnder, revealed that none of the UVs were likely
to cause splice defects. This analysis included do-
nor and acceptor site changes as well as inactiva-
tion of exonic splicing enhancer sequences.
These in silico experiments suggest that the
MLH3 UVs are likely to be benign, with the pos-
sible exception of p.Asn499Ser.
Transient Expression of MLH3 in
HEK293T Cells
To evaluate the stability of the WT- or
Mutant-YFP-MLH3 proteins, we transiently ex-
pressed Mutant-YFP-MLH3 in HEK293T cells.
Notably, HEK293T cells are deﬁcient for both
MLH1 and MLH3 due to hypermethylation of
the promoter regions of both genes (Cannavo
et al., 2005). The wildtype MLH3 protein was
stably expressed, even in the absence of MLH1
and the MLH3 expression levels of all UV-con-
taining proteins were comparable with the
expression level of the WT-YFP-MLH3 and
that of one known missense polymorphism
(p.Ser845Gly) (see Fig. 3A). The MLH3 pro-
tein variant with a frameshift mutation,
p.Ans860IfsX13, was not detectable (see Fig. 3A).
This was caused by shortening of the protein
leading to a loss of the epitope recognized by the
MLH3-antibody. The MLH3 (H-2) antibody is a
mouse monoclonal antibody raised against amino
acids 1228-1453 of human MLH3. To verify the
presence of the truncated protein, we reprobed
the blot with an anti-GFP antibody. A protein
with the size expected for the truncated protein
was detected (around 126 kDa), see Figure 3B.
These results suggest normal expression of all
UV-containing MLH3 proteins.
Subcellular Localization of MLH3
To evaluate whether the UV-containing
MLH3 proteins were transported correctly into
344 OU ETAL.
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the nucleus, WT-YFP-MLH3 and Mutant-YFP-
MLH3 were transfected into HEK293T cells or
into HeLa cells. Figure 4 shows representative
results of these experiments in HeLa cells (simi-
lar results were obtained in HEK293T cells, data
not shown). In the HeLa and HEK293T cell
lines, being MLH3-proﬁcient and -deﬁcient,
respectively, all mutated and WT proteins were
mainly localized in the nucleus. Some cytoplas-
matic staining was seen, although this was inde-
pendent of the presence of MLH1. These results
suggest that the subcellular localization of the
mutated proteins is normal. The subcellular local-
ization for the MLH3 protein containing a trun-
cating mutation clearly differs from the UV-
containing mutations since, besides the nuclear
staining, a strong cytoplasmatic staining was also
observed.
Yeast Two-Hybrid Analysis
To determine whether MLH1 and UV-contain-
ing or wildtype MLH3 are able to form protein
dimers in vivo, we performed a yeast two-hybrid
screen. The screen, as shown in Figure 5, showed
the MLH3 UVs analyzed, one known MLH3
missense polymorphism (p.Ser845Gly), and
the MLH3 frameshift mutation identiﬁed (see
Table 1). All mutated MLH3 proteins were able
to interact with WT-MLH1 and this interaction
was comparable with WT-MLH3-WT-MLH1
interaction and with that of the known missense
polymorphism. The data suggest that the UV-
containing MLH3 proteins can bind to WT-
MLH1 in vivo.
The control experiments also showed colonies
for the combination of the two empty vectors and
the combination of pAS2 (empty vector) with
Figure 2. Alignment of the human MLH3 protein with MLH3 pro-
teins of different vertebrates. The alignment includes the (putative)
MLH3 proteins of the following organism: Homo sapiens, Rattus norve-
gicus, Mus musculus, Canis familiaris, Bos taurus, Gallus gallus, Xenopus
tropicalis, Pan troglodytes, and Saccharomyces cerevisiae. Only protein
regions that contain the tested UVs are presented in this ﬁgure. The
conservation is depicted in colors (blue represents badly conserved
residues and red represents the best conserved residues). The multi-
ple sequence alignment was performed using the M-COFFEE pro-
gram. Although not depicted the amino acids in front of p.E624D and
p.A1394T are also highly conserved. [Color ﬁgure can be viewed in
the online issue, which is available at www.interscience.wiley.com.]
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pACT2-MLH3. The observed colonies, however,
were white whereas the colonies observed for the
WT-MLH1 with WT- or MUTANT-MLH3
were all blue, as expected. We also observed
interaction between the truncating MLH3 muta-
tion (p.Ans860IfsX13) and WT-MLH1.
DISCUSSION
Previously, nine MLH3 missense mutations and
an MLH3 frameshift mutation in patients sus-
pected of having Lynch syndrome were detected
(Wu et al., 2001). To clarify a possible role for
eight of these MLH3 UVs identiﬁed in suspected
Lynch syndrome patients, we performed several
biochemical tests.
Transfection of mutant and WT-MLH3 in an
MLH3-deﬁcient cell line, HEK293T, showed no
difference in protein levels for the UVs tested.
Our data also showed that the MLH3 protein is
stable without a heterodimeric or other partner,
corroborating previous ﬁndings (Cannavo et al.,
2005). To repair mismatches in vivo, the MLH3
protein needs to be present in the nucleus.
Recent localization experiments (Korhonen et al.,
2007) suggested that endogenous MLH3 is
mainly localized in the cytoplasm whereas MLH1
and PMS2 are localized in the nucleus in a
human MMR-proﬁcient cell line. It was also
shown by Korhonen et al. (2007) that when
MLH3 was transiently expressed in HCT116 (a
human cell line deﬁcient for MLH1 and PMS2),
the MLH3 protein also localized in the cyto-
plasm. Only after cotransfection with MLH1,
Korhonen et al. (2007) saw that MLH3 was par-
tially transported into the nucleus. They con-
clude that nuclear localization of MLH3 is
dependent on MLH1 and competitive with
PMS2. Our data do not corroborate these ﬁndings
as we observed with experiments performed in
two independent labs that both WT and UV-con-
taining MLH3 proteins were largely located in
the nucleus and only partially in the cytoplasm,
regardless of whether MLH3 was transfected
alone or cotransfected with MLH1 and regardless
of the cell line we used for transfection. When
transfecting the vector expressing the truncated
MLH3 protein (p.Asn860IfsX13) however, more
cytoplasmatic staining can clearly be seen (see
Fig. 4). The protein, however, is normally not
expressed as the naturally occurring unprocessed
mRNA containing such a frameshift mutation
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Figure 3. A: Expression of UV-containing and wildtype MLH3 in
HEK293T cells. This Western blot, using an MLH3 speciﬁc antibody,
shows no differences in MLH3 expression on comparing cells trans-
fected with WT-MLH3 and those transfected with UV-containing
MLH3. B: Expression of MLH3 in HEK293T cells. This Western blot,
using a GFP antibody shows in all but one lane the expected band of
190 kDa. In lane 7 (extracts from cells transfected with
p.Asn860lfsX13-MLH3), a lower band is visible (126 kDa). Data
shown are representative of three independent experiments. In this
ﬁgure, an aspeciﬁc band of 150 kDa is visible in all lanes.
Figure 4. Subcellular localization of CFP-MLH1 and YFP-MLH3, WT-MLH3, the UV-containing
MLH3s, and one truncating mutation containing MLH3 in HeLa cells. [Color ﬁgure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
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To study whether the identiﬁed MLH3 UVs
inﬂuence the interaction with MLH1 in vivo, we
tested the MLH3 mutants in a yeast two-hybrid
system. Yeast two-hybrid studies showed that all
of the analyzed MLH3 mutants were able to
interact with WT-MLH1 and that these interac-
tions were comparable with a WT-MLH3-WT-
MLH1 interaction. Surprisingly, we also observed
interaction between the truncating MLH3 muta-
tion (p.Asn860IfsX13) and WT-MLH1. A plausi-
ble explanation for this would be that a truncated
MLH3 protein is produced, as shown in Figure
3B (see Results section, protein expression/stabil-
ity studies). This truncated protein might still be
able to interact with MLH1 to form a hetero-
dimer with MLH1. Notably, the N-terminal
MLH1 interaction domain was still present in the
truncated form of MLH3, whereas the entire
COOH-terminal MLH1 interaction domain was
lacking (Fig. 1).
In conclusion, these biochemical assays do not
show a change in the function of the mutated
proteins we tested. Not ﬁnding a functional
defect in these assays does, however, not
preclude the MLH3 UVs being involved in
Lynch syndrome. The assays described above
Figure 5. ß-gal assays (yeast two-hybrid assays) for WT-MLH3, the
UV-containing MLH3s, and one truncating mutation containing MLH3.
The ﬁrst ten panels from left till right show the interaction between
MLH3 (with the indicated UV) with WT-MLH1. Panel 11. MLH3
coupled to the GAL4 activation domain instead of the GAL4 DNA
binding domain (as used in all other experiments) combined with
empty vector, Panel 12. WT-MLH1 combined with empty vector,
Panel 13. MLH1 (with a truncating mutation) combined with WT-
MLH3, Panel 14. WT-MLH3 combined with an empty vector, Panel
15. Two empty vectors. [Color ﬁgure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
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investigate only speciﬁc biochemical aspects of
MMR protein. It is conceivable that the UVs
tested can cause a functional defect of the pro-
tein that was not detectable with the assays used
in this study. We cannot therefore fully exclude
these UVs from being pathogenic.
Besides data from biochemical assays, we also
collected theoretical arguments that might help
in determining the pathogenic nature of the
MLH3 amino acid substitutions identiﬁed. We
determined conservation in nine organisms and
showed that seven of the amino acids that were
mutated are highly conserved (Fig. 2). We also
looked for polarity changes and saw again that
several of the UVs give rise to substantial
changes in polarity. However, when all of the
data of the in silico analyses were analyzed we
had to conclude that only based on Polyphen one
of the eight UVs could be considered as possibly
causative. The PolyPhen software combines
structural, evolutionary and physicochemical
properties. Notably, validation of the program
showed a proper prediction in only 80% of known
deleterious mutations, and thus false-positive or -
negative ﬁndings can be expected (Sunyaev
et al., 2000; Ng and Henikoff, 2002). However,
the prediction results are in line with the bio-
chemical assays described above, with the excep-
tion of p.Asn499Ser, which was predicted to be
possibly damaging. Our in silico analysis on splic-
ing showed that splicing abnormalities were not
predicted for any of the UVs.
On the basis of the results from the biochemi-
cal assays and the theoretical prediction algo-
rithms, we conclude that we have no convincing
evidence that the MLH3 UVs tested are involved
in the development of Lynch syndrome.
The above ﬁndings leave us with the question
whether mutations in MLH3 can contribute to
the development of Lynch syndrome? Our data
do not support any involvement of the MLH3
UVs identiﬁed in Lynch syndrome. Our data are
supporting a recent study on the MLH3 missense
mutations p.Q24E, p.S817G, p.A1494T, and
p.E1451K that were also biochemically evaluated
in our study. Korhonen et al., (2008) show that
these substitutions and three others (p.R647C,
G933C, and W1276R) do not affect in vitro mis-
match repair. Whether or not MLH3 UVs involve-
ment in Lynch syndrome can be concluded for
the two reported MLH3 frameshift mutations
(Wu et al., 2001; Liu et al., 2003) remains unan-
swered. The fact that the tumors of these
patients were MSI-low might be an argument
against involvement in tumorigenesis. On the
other hand, the ﬁnding of somatic mutations,
knocking out the second allele in the tumor in
three of the nine patients, argues in favor of their
involvement (Wu et al., 2001). Importantly, these
patients do not carry a germline mutation in one
of the other important MMR genes (based on
DNA sequence analysis and immunohistochemis-
try stainings) that could account for the second
hit of MLH3. Furthermore, PMS2 screening was
performed for the carriers of MLH3 missense
mutations p.Gln24Glu or p.Ala1494Thr and
PMS2 is not mutated in these patients. Finding
MSI-L tumors in the MLH3 frameshift mutation
carriers should also be no surprise since it was
shown that only a small but signiﬁcant (20%)
repair of both G/T mismatches and þ1 insertion/
deletion loop substrates was observed when
MMR-deﬁcient HEK293T nuclear protein
extracts were supplemented with high amounts
of MUTLc. This suggests that MUTLc might
play a backup role in human MMR (Cannavo
et al., 2005). In addition, it might be that MLH3
is more involved in tetranucleotide instability as
shown in Table 1. In the article of Wu et al.,
(2001) it has already been shown that the use of
ﬁve most informative markers (3 dinucleotide
and 2 tetranucleotide markers) show that 77% of
the tumors of MLH3 missense mutation carriers
show an MSI-H phenotype.
A low activity is also reﬂected in the presence
of low amounts of endogenous MLH3 protein in
human cell lines. Semiquantitative Western anal-
ysis of HeLa cells revealed endogenous MLH3
levels 60 times less abundant than PMS2 and 6
times less abundant than PMS1 (Cannavo et al.,
2005). Finally, as previously shown by others
(Cannavo et al., 2005), and now conﬁrmed in
this study, MLH3 is stable in the absence of
MLH1. As the other proteins that are facultative
partners of MMR components (PMS2, MSH6),
are unstable in the absence of their partner,
MLH3 seems to behave differently compared
with the other MMR proteins which could be
seen as an argument against involvement in
MMR.
In conclusion, we analyzed the functional sig-
niﬁcance of eight MLH3 UVs by in silico analyses
and biochemical assays. Our assays show that the
MLH3 UVs are likely to be as functional as the
wildtype MLH3 protein, suggesting that MLH3 is
not a major player in Lynch syndrome. However,
we cannot fully exclude a role for MLH3 as a
modiﬁer in tumorigenesis.
CHARACTERIZATION OF MLH3 UNCLASSIFIED VARIANTS 349
Genes, Chromosomes & Cancer DOI 10.1002/gcc
ACKNOWLEDGMENTS
The authors thank Dr. Steven Lipkin, Depart-
ments of Biological Chemistry and Medicine,
University of California, Irvine, USA for provid-
ing MLH3. The authors thank Jackie Senior for
editing the text.
REFERENCES
Betts MJ, Russell RB. 2003. Amino acid properties and conse-
quences of subsitutions. In: Barnes MR, Gray IC, editors. Bioin-
formatics for Geneticists. West Sussex (UK): John Wiley &
Sons, pp. 289–316.
Bradford MM. 1976. A rapid and sensitive method for the quanti-
tation of microgram quantities of protein utilizing the principle
of protein-dye binding. Anal Biochem 72:248–254.
Cannavo E, Marra G, Sabates-Bellver J, Menigatti M, Lipkin SM,
Fischer F, Cejka P, Jiricny J. 2005. Expression of the MutL
homologue hMLH3 in human cells and its role in DNA mis-
match repair. Cancer Res 65:10759–10766.
Chen PC, Dudley S, Hagen W, Dizon D, Paxton L, Reichow D,
Yoon SR, Yang K, Arnheim N, Liskay RM, Lipkin SM. 2005.
Contributions by MutL homologues Mlh3 and Pms2 to DNA
mismatch repair and tumor suppression in the mouse. Cancer
Res 65:8662–8670.
Chen PC, Kuraguchi M, Velasquez J, Wang Y, Yang K, Edwards
R, Gillen D, Edelmann W, Kucherlapati R, Lipkin SM. 2008.
Novel roles for MLH3 deﬁciency and TLE6-like ampliﬁcation
in DNA mismatch repair-deﬁcient gastrointestinal tumorigenesis
and progression. PLoS Genet 4:e1000092.
Chung DC, Rustgi AK. 2003. The hereditary nonpolyposis color-
ectal cancer syndrome: genetics and clinical implications. Ann
Intern Med 138:560–570.
Flores-Rozas H, Kolodner RD. 1998. The Saccaromyces cerevisiae
MLH3 gene functions in MSH3-dependent suppression of fra-
meshift mutations. Proc Natl Acad Sci USA 95:12404–12409.
Grantham R. 1974. Amino acid difference formula to help explain
protein evolution. Science 185:862–864.
Harfe BD, Minesinger BK, Jinks-Robertson S. 2000. Discrete in
vivo roles for the MutL homologs Mlh2p and Mlh3p in the re-
moval of frameshift intermediates in budding yeast. Curr Biol
10:145–148.
Jiricny J. 2006. The multifaceted mismatch-repair system. Nat
Rev Mol Cell Biol 7:335–346.
Kim JC, Roh SA, Yoon YS, Kim HC, Park IJ. 2007. MLH3 and
EXO1 alterations in familial colorectal cancer patients not ful-
ﬁlling Amsterdam criteria. Cancer Genet Cytogenet 176:172–
174.
Kondo E, Horii A, Fukushige, S. 2001. The interacting domains
of three MutL heterodimers in man: hMLH1 interacts with 36
homologous amino acid residues within hMLH3, hPMS1 and
hPMS2. Nucl Acid Res 29:1695–1702.
Korhonen MK, Raevaara TE, Lohi H, Nystrom M. 2007. Condi-
tional nuclear localization of hMLH3 suggests a minor activity
in mismatch repair and supports its role as a low-risk gene in
HNPCC. Oncol Rep 17:351–354.
Korhonen MK, Vuorenmaa E, Nystro¨m M. 2008. The ﬁrst func-
tional study of MLH3 mutations found in cancer patients. Genes
Chromosomes Cancer 47:803–809.
Liberti SE, Rasmussen LJ. 2004. Is hEXO1 a cancer predisposing
gene? Mol Cancer Res 2:427–432.
Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD,
Lynch HT, Elliott RM, Collins FS. 2000. MLH3: A DNA mis-
match repair gene associated with mammalian microsatellite
instability. Nat Genet 24:27–35.
Liu HX, Zhou XL, Liu T, Werelius B, Lindmark G, Dahl N,
Lindblom A. 2003. The role of hMLH3 in familial colorectal
cancer. Cancer Res 63:1894–1899.
Liu HX, Li Y, Jiang XD, Yin HN, Zhang L, Wang Y, Yang J.
2006. Mutation screening of mismatch repair gene Mlh3 in fam-
ilial esophageal cancer. World J Gastroenterol 12:5281–5286.
Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV.
2006. Computational approaches for predicting the biological
effect of p53 missense mutations: A comparison of three
sequence analysis based methods. Nucleic Acids Res 34:1317–
25.
Moretti S, Armougom F, Wallace IM, Higgins DG, Jongeneel CV,
Notredame C. 2007. The M-Coffee web server: a meta-method
for computing multiple sequence alignments by combining al-
ternative alignment methods. Nucleic Acids Res 35 (Web
Server issue):W645–W648.
Ng PC, Henikoff S. 2002. Accounting for human polymorphisms
predicted to affect protein function. Genome Res 12:436–446.
Peltomaki P, Vasen H. 2004. Mutations associated with HNPCC
predisposition—Update of ICG-HNPCC/INSiGHT mutation
database. Dis Markers 20:269–276.
Perucho M. 1999. Correspondence re: C.R. Boland et al., A
National Cancer Institute workshop on microsatellite instability
for cancer detection and familial predisposition: Development
of international criteria for the determination of microsatellite
instability in colorectal cancer. Cancer Res 58:5248–5257, 1998.
Cancer Res 59:249–256.
Rasmussen LJ, Rasmussen M, Lee B, Rasmussen AK, Wilson
DM, III, Nielsen FC, Bisgaard HC. 2000. Identiﬁcation of fac-
tors interacting with hMSH2 in the fetal liver utilizing the yeast
two-hybrid system. In vivo interaction through the C-terminal
domains of hEXO1 and hMSH2 and comparative expression
analysis. Mutat Res 460:41–52.
Sunyaev SR, Lathe WC, III, Ramensky VE, Bork P. 2000. SNP
frequencies in human genes an excess of rare alleles and differ-
ing modes of selection. Trends Genet 16:335–337.
Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T,
Samollow PB, de Silva D, Zharkikh A, Thomas A. 2005. Com-
prehensive statistical study of 452 BRCA1 missense substitu-
tions with classiﬁcation of eight recurrent substitutions as
neutral. J Med Genet 43:295–305.
Taylor NP, Powell MA, Gibb RK, Rader JS, Huettner PC, Thibo-
deau SN, Mutch DG, Goodfellow PJ. 2006. MLH3 mutation in
endometrial cancer. Cancer Res 66:7502–7508.
Tishkoff DX, Boerger AL, Bertrand P, Filosi N, Gaida GM, Kane
MF, Kolodner RD. 1997. Identiﬁcation and characterization of
Saccharomyces cerevisiae EXO1, a gene encoding an exonuclease
that interacts with MSH2. Proc Natl Acad Sci USA 94:7487–
7492.
Tran PT, Simon JA, Liskay RM. 2001. Interactions of Exo1p with
components of MutLalpha in Saccharomyces cerevisiae. Proc Natl
Acad Sci USA 98:9760–9765.
Wu Y, Berends MJ, Sijmons RH, Mensink RG, Verlind E, Kooi
KA, van der ST, Kempinga C, van der Zee AG, Hollema H,
Buys CH, Kleibeuker JH, Hofstra RM. 2001. A role for MLH3
in hereditary nonpolyposis colorectal cancer. Nat Genet 29:137–
138.
350 OU ETAL.
Genes, Chromosomes & Cancer DOI 10.1002/gcc
